Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Locally advanced prostate cancer: a population-based study of treatment patterns.

Lowrance WT, Elkin EB, Yee DS, Feifer A, Ehdaie B, Jacks LM, Atoria CL, Zelefsky MJ, Scher HI, Scardino PT, Eastham JA.

BJU Int. 2012 May;109(9):1309-14. doi: 10.1111/j.1464-410X.2011.10760.x. Epub 2011 Nov 15.

2.
3.

Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study.

Dell'Oglio P, Abou-Haidar H, Leyh-Bannurah SR, Tian Z, Larcher A, Gandaglia G, Fossati N, Shariat SF, Capitanio U, Briganti A, Montorsi F, Graefen M, Saad F, Karakiewicz PI.

Eur Urol. 2016 Sep;70(3):429-35. doi: 10.1016/j.eururo.2016.02.057. Epub 2016 Mar 4.

PMID:
26951945
4.

Patterns of prostate cancer treatment by clinical stage and age.

Meltzer D, Egleston B, Abdalla I.

Am J Public Health. 2001 Jan;91(1):126-8.

5.

Physician visits prior to treatment for clinically localized prostate cancer.

Jang TL, Bekelman JE, Liu Y, Bach PB, Basch EM, Elkin EB, Zelefsky MJ, Scardino PT, Begg CB, Schrag D.

Arch Intern Med. 2010 Mar 8;170(5):440-50. doi: 10.1001/archinternmed.2010.1.

6.

Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States.

Gilbert SM, Kuo YF, Shahinian VB.

Urol Oncol. 2011 Nov-Dec;29(6):647-53. doi: 10.1016/j.urolonc.2009.09.004. Epub 2009 Nov 19.

7.

Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.

Hussain A, Wu Y, Mirmiran A, DiBiase S, Goloubeva O, Bridges B, Mannuel H, Engstrom C, Dawson N, Amin P, Kwok Y.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):167-74. doi: 10.1016/j.ijrobp.2010.09.009. Epub 2010 Oct 30.

PMID:
21036487
8.

Penile implant utilization following treatment for prostate cancer: analysis of the SEER-Medicare database.

Tal R, Jacks LM, Elkin E, Mulhall JP.

J Sex Med. 2011 Jun;8(6):1797-804. doi: 10.1111/j.1743-6109.2011.02240.x. Epub 2011 Mar 22.

PMID:
21426495
9.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
10.

Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.

Jang JW, Hwang WT, Guzzo TJ, Wein AJ, Haas NB, Both S, Vapiwala N.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1493-9. doi: 10.1016/j.ijrobp.2011.10.047. Epub 2012 Mar 6.

PMID:
22401922
11.

Tailored treatment including radical prostatectomy and radiation therapy + androgen deprivation therapy versus exclusive radical prostatectomy in high-risk prostate cancer patients: results from a prospective study.

Castelli T, Russo GI, Favilla V, Urzi D, Spitaleri F, Reale G, Giardina R, Saita A, Madonia M, Cimino S, Morgia G.

Int Braz J Urol. 2014 May-Jun;40(3):322-9. doi: 10.1590/S1677-5538.IBJU.2014.03.05.

12.

Radical prostatectomy for clinical T4 prostate cancer.

Johnstone PA, Ward KC, Goodman M, Assikis V, Petros JA.

Cancer. 2006 Jun 15;106(12):2603-9.

13.

Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.

Baade PD, Youlden DR, Gardiner RA, Ferguson M, Aitken JF, Yaxley J, Chambers SK.

BJU Int. 2012 Dec;110(11 Pt B):E712-9. doi: 10.1111/j.1464-410X.2012.011533.x. Epub 2012 Sep 27.

14.

Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.

Jackson WC, Schipper MJ, Johnson SB, Foster C, Li D, Sandler HM, Palapattu GS, Hamstra DA, Feng FY.

Eur Urol. 2016 Jan;69(1):50-7. doi: 10.1016/j.eururo.2015.05.009. Epub 2015 May 21.

PMID:
26004800
15.

Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer.

Bekelman JE, Mitra N, Handorf EA, Uzzo RG, Hahn SA, Polsky D, Armstrong K.

J Clin Oncol. 2015 Mar 1;33(7):716-22. doi: 10.1200/JCO.2014.57.2743. Epub 2015 Jan 5.

16.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators.

Cancer. 2006 Apr 15;106(8):1708-14.

17.

Ascertainment of postprostatectomy radiotherapy for prostate cancer in the Surveillance, Epidemiology, and End Results database.

Wang K, Sheets NC, Basak R, Chen RC.

Cancer. 2016 Oct;122(19):3069-74. doi: 10.1002/cncr.30154. Epub 2016 Jun 28.

18.

Use of Androgen Deprivation Therapy With Radiotherapy for Intermediate- and High-Risk Prostate Cancer Across the United States.

Falchook AD, Basak R, Mohiuddin JJ, Chen RC.

JAMA Oncol. 2016 Sep 1;2(9):1236-8. doi: 10.1001/jamaoncol.2016.1143. No abstract available.

PMID:
27367418
19.

Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years.

Abdollah F, Sammon JD, Reznor G, Sood A, Schmid M, Klett DE, Sun M, Aizer AA, Choueiri TK, Hu JC, Kim SP, Kibel AS, Nguyen PL, Menon M, Trinh QD.

Eur J Surg Oncol. 2015 Nov;41(11):1529-39. doi: 10.1016/j.ejso.2015.06.011. Epub 2015 Jul 15.

PMID:
26210655
20.

Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.

Song C, Kim YS, Hong JH, Kim CS, Ahn H.

BJU Int. 2010 Jul;106(2):188-93. doi: 10.1111/j.1464-410X.2009.09136.x. Epub 2009 Dec 11.

Supplemental Content

Support Center